Journal Information
Vol. 21. Issue 3.
Pages 105-108 (May - June 1985)
Share
Share
Download PDF
More article options
Vol. 21. Issue 3.
Pages 105-108 (May - June 1985)
Full text access
Toxicidad hepatica grave por drogas antituberculosas. Revision de 19 casos
Severe hepatic toxicity due to tuberculostatics. A review of 19 cases
Visits
6921
M.aL. Martinez Martinez, R. Vidal Pla, R. Esteban Mur, J. Ruiz Manzano, E. Fite Reig, E. Monso Molas
Sección de Neumología. Departamento de Medicina Interna. Ciudad Sanitaria Valle de Hebrón. Barcelona
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

Se revisan diecinueve pacientes que presentaron toxicidad hepática grave en el curso del tratamiento con drogas antituberculosas. Se comenta la incidencia de la he-patotoxicidad y la relación en ocasiones con factores predisponentes o con sobredosificación de dichas drogas. Puede aparecer en cualquier momento del tratamiento, aunque es más frecuente en los dos primeros meses; en más de la mitad de nuestros pacientes, la toxicidad hepática apareció en los primeros 15 días. Los síntomas son fundamentalmente digestivos. Observamos en 14 pacientes ictericia y en siete síntomas de insuficiencia hepática. Un paciente falleció y el resto recuperó la normalidad clínica y bioquímica entre los 4 y 30 días tras dejar el tratamiento antituberculoso. Estos reanudaron el tratamiento con drogas no hepatotóxicas siguiendo una evolución favorable hasta el final del tratamiento.

Nineteen patients with severe hepatic toxicity due to tuberculostatics were included in a study on the incidence of hepatic toxicity and the relationship with predisposing factors or drug overdose. Hepatic toxicity may appear at any time during treatment but occurs most frequently during the first two months after starting treatment; all 19 patients in our study presented toxicity within 15 days. Symptoms were principally digestive ones and 14 patients had ictericia and 7 presented symptoms of hepatic insuf-ficiency. One patient died. In the remaining 18 patients, clinical and biochemical data returned to normal within 4 to 30 days after suspension of the antituberculosis therapy. Treatment was continued with non-hepatotoxic drugs and elicited a favourable response in all patients.

Full text is only aviable in PDF
Bibliografia
[1.]
J.R. Mitchell, H.J. Zimmermam, K.G. Ishak, et al.
Isoniazid liver injury: Clinical spectrum, pathology and probable pathogenesis.
Ann Intern Med, 84 (1976), pp. 181-193
[2.]
H. Randolph, S. Joseph.
Toxic hepatitis with jaundice occurring in a patient treated with isoniazid.
JAMA, 152 (1953), pp. 38-40
[3.]
S.N. Gellis, R.V. Murphy.
Hepatitis following isoniazid.
Dis Chest, 28 (1955), pp. 462-463
[4.]
R. Cohen, M.H. Kasler, R.V. Thompson.
Fatal hepatic necrosis secondary to isoniazid therapy.
JAMA, 176 (1961), pp. 877-879
[5.]
R.A. Garibaldi, R.E. Drusin, S.H. Ferebee, M.B. Gregg.
Isoniazid-associated hepatitis Report of an outbreak.
Am Rev Respir Dis, 106 (1972), pp. 357-365
[6.]
L. Scharer, J.P. Smith.
Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.
Ann Intern Med, 71 (1969), pp. 1113-1120
[7.]
N. Riska.
Hepatitis cases in isoniazid treated groups and in control groups.
Bull Int Un Tuberc, 51 (1976), pp. 203-206
[8.]
M. Black, J.R. Mitchell, H.J. Zimmerman, K.G. Ishak, G.R. Epler.
Isoniazid-associated hepatitis in 114 patients.
Gastroenterology, 69 (1975), pp. 289-302
[9.]
D.E. Kopanoff, D.E. Snider, G.J. Casas.
Isoniazid-related hepatitis.
Am Rev Respir Dis, 117 (1978), pp. 991-1001
[10.]
J.M. Ladero Quesada.
Metabolismo y efectos hepáticos de la rifampicina.
Mun Far, 6 (1978), pp. 153-155
[11.]
P.J. Sheuer, J.A. Summerfield, S. Lal, S. Sherlock.
Rifampicin hepatitis clinical and hystological study.
[12.]
A.W. Lees, G.W. Allan, J. Smith, W.F. Tyrrell, R.J. Fallon.
Toxicity from rifampicin plus isoniazid and rifampicin plus ethambutol therapy.
Tubercle, 52 (1971), pp. 182-185
[13.]
S. Lal, S.N. Singal, D.M. Burdley, G. Grossley.
Effect of rifampicin and isoniazid on liver function.
Brit Med J, 1 (1972), pp. 148-153
[14.]
D.J. Girling.
The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide.
Tubercle, 59 (1978), pp. 13-32
[15.]
W. McDermott, L. Ormond, C. Muschenheim, K. Deuschle, R.M. McCune.
Pyrazinamide-isoniazid in tuberculosis.
Am Rev Respir Tuberc, 69 (1954), pp. 319-324
[16.]
R.B. Byrd, M.B.R. Horn, G.A. Griggs, M.D.A. Salomon.
Isoniazid chemoprophylaxis.
Arch Intern Med, 137 (1977), pp. 1130-1133
[17.]
C. Grönhagen-Riskar, P.E. Hellstrom, B. Fröseth.
Predisposing factors in hepatitis induced by isoniazid-rifampicin treatment of tuberculosis.
Am Rev Respir Dis, 118 (1978), pp. 461-466
[18.]
A.K.M. Bartelink, J.W.M. Lenders, C.L.A. Van Herwaarden, V.J.G. Van Haelst, J.H.M. Van Tongeren.
Fatal hepatitis after treatment witn isoniazid and rifampicin in a patient on anticonvulsant therapy.
Tubercle, 64 (1983), pp. 125-128
[19.]
W.C. Maddrey.
Isoniazid-induced liver disease. Druginduced liver disease.
Semminars in liver disease, 1 (1981), pp. 129-133
[20.]
R.S. Rapp, R.W. Campbell, J.C. Howell, E.L. Kendig jr..
Isoniazid hepatotoxicity in children.
Am Rev Respir Dis, 118 (1978), pp. 794-796
[21.]
G.W. Comstock, P.Q. Edwards.
The competing risk of tuberculosis and hepatitis for adult tuberculin reactors.
Am Rev Respir Dis, 111 (1975), pp. 573-577
[22.]
D. Pessayre, M. Bentata, C. Degott, et al.
Isoniazidrifampicin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction.
Gastroenterology, 72 (1977), pp. 284-289
[23.]
H.L. Israel.
Isoniazid-associated hepatitis.
Gastroenterology, 69 (1975), pp. 539-542
[24.]
H.J. Zimmerman, Hepatotoxicity.
The adverse effects of drugs and other chemicals in the liver.
ApplentonCentry-Crofs, (1978), pp. 487-491
[25.]
W.C. Maddrey, J.K. Boitnott.
Isoniazid hepatitis.
Ann Intern Med, 79 (1973), pp. 1-12
[26.]
G.A. Ellard, P.T. Gammon.
Pharmacokinetics of isoniazid metabolism in man.
Jour Pharmacokin Biopharmac, 4 (1976), pp. 83-86
[27.]
J.R. Mitchell, M.W. Long, V.P. Thorgeirsson, V.J. Jollows.
Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.
Chest, 68 (1975), pp. 181-184
[28.]
P. Scheuer, J.A. Summerfield, S. Lal, et al.
Rifampicin hepatitis. A clinical and histological study.
[29.]
A.D. Merritt, B.F. Fetter.
Toxic hepatic necrosis (hepatitis) due to isoniazid: report of a case with cirrhosis and death due to hemorrhage from esophageal varices.
Ann Intern Med, 50 (1959), pp. 804-810
[30.]
W.C. Maddrey, J.K. Boitnott.
Drug-induced chronic hepatitis and cirrhosis.
Progress in Liver Disease Vol VI, pp. 595-603
Copyright © 1985. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?